Novo Nordisk has agreed to acquire Akero Therapeutics, a clinical-stage company that develops treatments for metabolic diseases, the company announced last week. Akero’s EFX pipeline Akero Therapeutics’ treatment for metabolic-dysfunction-associated steatohepatitis (MASH) “is closely linked with Novo Nordisk’s expertise in diabetes and obesity,” the press release stated. More than 40% of patients with MASH, formerly…
M&A strong at the dawn of 2024, but it’s too early to tell if it will match 2023 levels
The biopharma sector appears to be gearing up for a dynamic year of merger and acquisition activity in 2024. Analysts at EY indicate the sector could see between $225 billion and $275 billion in total deal value, in line with 2023’s roughly $238 billion. In the first 24 days of January this year, there were…